Orchestra Biomed To Present Data Summary Supporting Transformative Potential Of AVIM Therapy In Management Of Hypertensive Heart Disease At Georgia Innovation Summit In Tbilisi

• Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progression of hypertensive heart disease
• Orchestra BioMed and Medtronic (NYSE:MDT) have a strategic collaboration to develop and commercialize AVIM Therapy for the treatment of uncontrolled hypertension in patients indicated for a pacemaker, an estimated global population of over 750,000 patients annually
• AVIM Therapy has received FDA Breakthrough Device Designation for the treatment of uncontrolled hypertension in patients with increased cardiovascular risk, an estimated U.S. population of over 7.7 million patients

NEW HOPE, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced a data summary supporting the transformative potential of Atrioventricular Interval Modulation ("AVIM") Therapy in the management of hypertensive heart disease will be presented in a keynote talk at the Georgia Innovation Summit in Tbilisi, Georgia on October 10, 2025. The presentation, to be delivered by Avi Fischer, MD, Senior Vice President of Medical Affairs and Innovation at Orchestra BioMed, will showcase AVIM Therapy as a novel, device-based therapeutic approach targeting hypertensive heart disease progression and its potential to redefine standards of care.